BioNTech and CEPI Announce Partnership to Advance mRNA Mpox

BioNTech is initiating a Phase 1/2 clinical trial of the mRNA-based mpox vaccine program, BNT166The Coalition for Epidemic Preparedness Innovations (CEPI) commits funding of up to $90 million for the

Related Keywords

United Kingdom , Norway , Rwanda , Germany , Kigali , W09 , Kate Kelland , Ugur Sahin , Richard Hatchett , Fosun Pharma , Days Mission , Regulatory Agency , United Kingdom Health Security Agency , Coalition For Epidemic Preparedness Innovations , Days Mission To End Pandemics , Linkedin , Genentech , Roche Group , Pfizer , World Health Organization Foundation , Exchange Commission , Epidemic Preparedness Innovations , Chief Executive Officer , New Technologies , Private Securities Litigation Reform Act , Ebola Virus Disease , Middle East Respiratory Syndrome , Rift Valley Fever , End Pandemics , Scientific Writer Kate Kelland , United Kingdom Medicines , National News ,